We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biovail Laboratories has filed a lawsuit in federal court against generic firm
Impax over its bid to launch a generic version of Biovail's Wellbutrin XL, an
antidepressant marketed by GlaxoSmithKline.
The FDA has issued a warning letter to custom
chemical company DanChem for failing to meet current good manufacturing practices
(cGMPs) in its production of active pharmaceutical ingredients (APIs).
The Justice Department is investigating GlaxoSmithKline's (GSK) use of nominal
pricing arrangements to determine whether the pricing strategy violates Medicaid
price-reporting rules.
Seattle Genetics, Inc. announced that it has achieved a milestone under its
antibody-drug conjugate (ADC) collaboration agreement with Genentech, triggering
an undisclosed payment to Seattle Genetics.
Titan Pharmaceuticals Inc. said it lost $7.8 million in the fourth quarter ended
December, compared with a loss of $10.5 million in the same quarter a year ago.
Amazon Biotech, a developer and producer of AMZ 0026, a potential immunomodulator
drug developed for use in the treatment of the HIV virus, announced that it
has raised a total of $618,500 in gross proceeds in equity capital private placements
since February 2004.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company with a broad portfolio
of products under development, announced financial results for the third quarter
ended Jan. 31, 2005.
Icagen, Inc. announced that it has received a milestone payment from Yamanouchi
Pharmaceutical Co., Ltd. related to the selection of a compound for advanced
preclinical studies as a result of the collaboration between the two companies
in dementia, including Alzheimer's disease.